Search Results

Veracyte, Inc. announced it has reached the terms of an agreement to acquire HalioDx in a transaction to further accelerate growth and strengthen Veracyte’s global leadership in cancer diagnostics.

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), a clinical-stage biotechnology company focused on developing innovative immunotherapies, and HalioDx, the immuno-oncology diagnostic company, today announced a collaboration to conduct a translational investigation of immune biomarkers as part of the ongoing Phase 3 clinical trial of neoepitope combination Tedopi® in non-small cell lung cancer (NSCLC) patients.

OncoDNA, a theranostic and genomic company specializing in precision oncology, has announced that it has signed a subcontract service agreement with HalioDx’s U.S.-based CLIA-certified laboratory located in Richmond, Virginia.

This fundraising is intended to accelerate the development of Immunoscore for colon cancer and selected additional cancer types and set up commercial activities in the U.S.

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024.